Skip to content

United Therapeutics UTHR Adcirca — Total revenues

Other product segments

Tyvaso DPI
$330.3M+9.2%
Orenitram
$135.6M+12.3%
Nebulized Tyvaso
$127.2M-22.3%
Remodulin
$126.6M-8.4%
Unituxin
$53.6M-7.9%

Similar metrics at other companies

Cumberland Pharmaceuticals logo
CPIXAcetadote — Revenue
$51.98K-65.7%
Open Text logo
OTEXADM — Total revenues
$29.41M+10.7%
IBT
IBTAAd & other revenue — Total Revenue
$9.47M-15.3%
Incyte logo
INCYTABRECTA — Total revenues
$6M-6.3%
BH
BHAdvertising — Total revenues
$862K+4.8%
BioMarin Pharmaceuticals logo
BMRNALDURAZYME — Total revenues
$36.74M-25.0%

Other financials

Income statement

See full
Revenue$781.5M-1.6%
Gross profit$648.1M-7.7%
Operating income$325.8M-14.9%
Net income$274.9M-14.7%
EPS (diluted)$5.82-12.2%

Balance sheet

See full
Cash & equivalents$1.3B-32.6%
Total debt$12.2M
Total equity$5.9B-13.3%
Total assets$6.7B-13.3%

Cash flow

See full
Operating cash flow$463.3M+0.5%
CapEx$100.8M+34.6%
Free cash flow$362.5M-6.2%

Valuation

See full
Market cap$23B+84.1%
P/E17.9×+7.8×
P/S7.3×+3.2×

Profitability

See full
Gross margin86.6%-2.4pp
Operating margin45.3%-1.6pp
Net margin40.6%+0.2pp
FCF margin32.1%-5.6pp

Returns & leverage

See full
Return on equity20.3%+0.3pp
Debt / equity
Current ratio4.8×-0.7×

Where this comes from

Reported directly by United Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: United Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about United Therapeutics's adcirca — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is United Therapeutics's adcirca — total revenues?
United Therapeutics (UTHR) reported adcirca — total revenues of $2.9M in Q1 2026.
How has United Therapeutics's adcirca — total revenues changed year-over-year?
United Therapeutics's adcirca — total revenues decreased by 51.7% year-over-year, from $6M to $2.9M.
What is the long-term trend for United Therapeutics's adcirca — total revenues?
Over 4 years (2021 to 2025), United Therapeutics's adcirca — total revenues has grown at a -14.4% compound annual growth rate (CAGR), from $55.9M to $30M.
What does adcirca — total revenues mean?
Represents the total gross revenue generated from the sale of a specific pharmaceutical product or therapeutic line. This metric tracks the top-line performance of the product before accounting for any cost of goods sold or operating expenses.